7-iodo-N-acetyl-1,2,3,4-tetrahydroisoquinoline | 220247-65-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 7-iodo-N-acetyl-1,2,3,4-tetrahydroisoquinoline
• 英文别名: 2-acetyl-7-iodo-1,2,3,4-tetrahydroisoquinoline；1-(7-iodo-3,4-dihydroisoquinolin-2(1H)-yl)ethanone；1-(7-iodo-3,4-dihydro-1H-isoquinolin-2-yl)ethanone
• CAS: 220247-65-4
• 化学式: C₁₁H₁₂INO
• 分子量: 301.127
• InChiKey: MPMUBOXVZUJKLY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  7-iodo-N-acetyl-1,2,3,4-tetrahydroisoquinoline 在 盐酸 、 sodium hydroxide 作用下， 以 乙醇 、 水 、 甲醇 为溶剂， 反应 18.0h， 以97%的产率得到7-碘-1,2,3,4-四氢异喹啉盐酸盐
  参考文献：
  名称：

  [EN] CHEMICAL COMPOUNDS
  [FR] COMPOSES CHIMIQUES

  摘要：

  本发明公开了嘧啶衍生物，含有该嘧啶衍生物的组合物和药物，以及制备和使用这些化合物、组合物和药物的方法。这些嘧啶衍生物在治疗与不适当的ErbB家族激酶相关的疾病中很有用。

  公开号：

  WO2005016914A1
• 作为产物：
  描述：

  1-(7-氨基-3,4-二氢-2(1h)-异喹啉)乙酮 在 盐酸 、 sodium nitrite 、 copper(l) iodide 、 potassium iodide 作用下， 以 水 、 氯仿 为溶剂， 反应 13.5h， 以86%的产率得到7-iodo-N-acetyl-1,2,3,4-tetrahydroisoquinoline
  参考文献：
  名称：

  [EN] CHEMICAL COMPOUNDS
  [FR] COMPOSES CHIMIQUES

  摘要：

  本发明公开了嘧啶衍生物，含有该嘧啶衍生物的组合物和药物，以及制备和使用这些化合物、组合物和药物的方法。这些嘧啶衍生物在治疗与不适当的ErbB家族激酶相关的疾病中很有用。

  公开号：

  WO2005016914A1

文献信息

• Chemical compounds
  申请人：Reno John Michael

  公开号：US20060205740A1

  公开（公告）日：2006-09-14

  The present invention discloses pyrimidine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such pyrimidine derivatives are useful in the treatment of diseases associated with inappropriate ErbB family kinase.

  本发明揭示了嘧啶衍生物、含有该嘧啶衍生物的组合物和药物，以及制备和使用这些化合物、组合物和药物的方法。这些嘧啶衍生物在治疗与不适当的ErbB家族激酶相关的疾病方面具有用途。
• CHEMICAL COMPOUNDS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1654251A1

  公开（公告）日：2006-05-10
• EP1654251A4
  申请人：——

  公开号：EP1654251A4

  公开（公告）日：2009-03-11
• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSES CHIMIQUES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2005016914A1

  公开（公告）日：2005-02-24

  The present invention discloses pyrimidine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such pyrimidine derivatives are useful in the treatment of diseases associated with inappropriate ErbB family kinase.

  本发明公开了嘧啶衍生物，含有该嘧啶衍生物的组合物和药物，以及制备和使用这些化合物、组合物和药物的方法。这些嘧啶衍生物在治疗与不适当的ErbB家族激酶相关的疾病中很有用。
• Synthesis, Biochemical Evaluation, and Classical and Three-Dimensional Quantitative Structure−Activity Relationship Studies of 7-Substituted-1,2,3,4-tetrahydroisoquinolines and Their Relative Affinities toward Phenylethanolamine <i>N</i>-Methyltransferase and the α₂-Adrenoceptor^,1
  作者：Gary L. Grunewald、Vilas H. Dahanukar、Ravi K. Jalluri、Kevin R. Criscione

  DOI：10.1021/jm980429p

  日期：1999.1.1

  7-Substituted-1,2,3,4-tetrahydroisoquinolines (7-substituted-THIQs) are potent inhibitors of phenylethanolamine N-methyltransferase (PNMT, EC 2.1.1.28), the enzyme involved in the biosynthesis of epinephrine. Unfortunately, most of these compounds also exhibit strong affinity for the aa-adrenoceptor. To design a selective (PNMT vs alpha(2)-adrenoceptor affinity) inhibitor of PNMT, the steric and electrostatic factors responsible for PNMT inhibitory activity and alpha(2)-adrenoceptor affinity were investigated by evaluating a number of 7-substituted-THIQs. A classical quantitative structure-activity relationship (QSAR) study resulted in a three-parameter equation for PNMT (PNMT pK(i) = 0.599 pi - 0.0725MR + 1.55 sigma(m) + 5.80; n = 27, r = 0.885, s = 0.573) and a three-parameter equation for the alpha(2)-adrenoceptor (alpha(2) pK(i) = 0.599 pi - 0.0542MR - 0.951 sigma(m) + 6.45; n = 27, r = 0.917, s = 0.397). These equations indicated that steric effects and lipophilicity play a similar role at either active site but that electronic effects play opposite roles at either active site. Two binding orientations for the THIQs were postulated such that lipophilic and hydrophilic 7-substituents would not occupy the same region of space at either binding site. Using these two binding orientations, based on the lipophilicity of the 7-substituent, comparative molecular field analysis (CoMFA) models were developed that showed that the steric and electrostatic interactions at both sites were similar to those previously elaborated in the QSAR analyses. Both the QSAR and the CoMFA analyses showed that the steric interactions are similar at the PNMT active site and at the alpha(2)-adrenoceptor and that the electrostatic interactions were different at the two sites. This difference in electrostatic interactions might be responsible for the selectivity of THIQs bearing a nonlipophilic electron-withdrawing group at the 7-position, These QSAR and CoMFA results will be useful in the design of potent and selective (PNMT vs alpha(2)-adrenoceptor affinity) inhibitors of PNMT.